AstraZeneca’s Soriot Says Mega-Mergers Can Work, But Is Hush Hush On Pfizer
This article was originally published in The Pink Sheet Daily
Executive Summary
AstraZeneca did not address rumors it has become an acquisition target of Pfizer during its first quarter conference call. CEO Soriot did say that some mega-mergers can work, but such deals have to be evaluated on a case-by-case basis.
You may also be interested in...
Emerging Market Earnings Roundup: China Surpasses Japan As AstraZeneca’s Second Largest Market (Part 4)
China is now AstraZeneca’s second largest market where it out grew multinational peers including Pfizer in the first quarter.
AstraZeneca Hopes Bydureon Pen Will Rewrite GLP-1 Story
FDA approved an easier-to-use pen version of Bydureon for the treatment of type 2 diabetes, but AstraZeneca will need to move quickly and effectively with the launch if it is to establish the brand before other long-acting GLP-1’s enter the market.
AZ Doubles Down On Diabetes, Buys Out Bristol’s Share in Alliance
AstraZeneca will acquire all of Bristol’s interests in their current diabetes alliance. In doing so, AZ believes its geographic reach and scale in assets and capabilities position it to succeed, while Bristol retreats from diabetes to focus on specialty biologics, notably its PD-1 franchise.